focus -WSS

focus

author：knowledge 2025-08-11 07:58:59 - browse：64397

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

leisure time

WSS

FDA poised to publish guidelines for clinical trial diversity

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Bird flu surveillance in wastewater gets boost from consortium

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

The simple reason for the increase in autism diagnosis

Medical experts exlpore how to eliminate bias in clinical algorithms

Wikipedia

focus

focus

Duchenne breakthrough therapy leaves behind pioneering families

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

United colonoscopy coverage change 'may cost lives,' doctors say

Biogen joins immunology wave with $1.15 billion acquisition of HI

As demand for Covid shots wanes, Moderna seeks its next success

Supreme Court rules employers must be more accommodating of religious observance

Bright Health sells Medicare Advantage business to Molina

Making the case for fair compensation in clinical trials

Medicare details structure of new drug price negotiation program

ADA: All diabetes patients should be screened for liver condition

hotspot

Here's how to stay safe from wildfire smoke amid reduced air quality

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Why do we get seasonal allergies?

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

At flashy new research hub, AstraZeneca lays out ambitious growth goals

FDA poised to publish guidelines for clinical trial diversity

leisure time

focus

leisure time

Wikipedia